Browse News
Filter News
Found 804,924 articles
-
Following in the footsteps of Bristol Myers Squibb and Eli Lilly, AstraZeneca on Tuesday jumped into the radiopharmaceuticals space by acquiring Fusion Pharmaceuticals in a deal worth $2.4 billion.
-
Orchard Therapeutics on Monday secured the FDA’s first approval for an autologous gene therapy to treat the rare metabolic disease metachromatic leukodystrophy in children.
-
Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
3/19/2024
Conduit Pharmaceuticals Inc. announced the appointment of Dr. Joanne Holland as Chief Scientific Officer.
-
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
3/19/2024
Revive Therapeutics Ltd. announced that the FDA advised the Company to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID.
-
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
3/19/2024
Tourmaline Bio, Inc. announced its financial results for the fourth quarter and year ended December 31, 2023 and outlined recent business highlights.
-
LSL Pharma Group Secures $6.44 Million as the First Closing of Concurrent Non-Brokered Private Placements
3/19/2024
LSL PHARMA GROUP INC., a Canadian integrated pharmaceutical company, announced the closing on March 18, 2024 of non-brokered private placements for $6.44 million representing the first closing of the $8.0 million combined financings announced on March 7, 2024.
-
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
3/19/2024
Axsome Therapeutics, Inc. announced the first patient has been dosed in the PARADIGM Phase 3 trial of solriamfetol, an investigational treatment for major depressive disorder.
-
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
3/19/2024
Century Therapeutics announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET.
-
Kraig Biocraft Laboratories Brings Leading Sericulture Expert from India for Launch of Spring Production Trials
3/19/2024
Kraig Biocraft Laboratories, Inc., announces that Dr. Nirmal Kumar, a globally recognized expert in sericulture, will join the Company’s Senior Management in Vietnam to supervise the start of the spring production trials and the launch of the BAM-1 hybrid.
-
SPEVIGO® approved for expanded indications in China and the US
3/19/2024
Boehringer Ingelheim announced that the US FDA has approved SPEVIGO® injection for the treatment of generalized pustular psoriasis in adults and pediatric patients aged 12 and above weighing ≥40 kg.5 This approval follows the Chinese National Medical Products Administration’s recent approval of SPEVIGO® for the reduction of occurrence of generalized pustular psoriasis in adolescents from 12 years of age with a body weight ≥40 kg and adults.
-
Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study
3/19/2024
Asieris Pharmaceuticals announced that the multicenter Phase III global clinical study data of its non-surgical treatment for cervical HSIL product APL-1702 demonstrated significant efficacy and good safety profile, with new advancements in clearance rate of high-risk HPV16 and/or HPV18.
-
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis
3/19/2024
Vicore Pharma Holding AB announced FDA Breakthrough Device Designation status for AlmeeTM, a 9-week digital cognitive behavioral therapy, to be used as an adjunct treatment of anxiety symptoms related to PF.
-
CGI selected by Centers for Medicare & Medicaid Services to improve Medicare access for more than 65 million beneficiaries nationwide
3/19/2024
CGI Federal Inc., a wholly-owned U.S. operating subsidiary of CGI Inc., has been awarded a single award, firm-fixed price contract by the Centers for Medicare & Medicaid Services to help improve access to Medicare for millions of beneficiaries by modernizing the agency's Health Plan Management System.
-
Sanyou Bio and BioGeometry join forces to create a next-generation Antibody Drug Discovery Platform driven by AIGC
3/19/2024
Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement.
-
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
3/19/2024
Pluri Inc., a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, announced its participation in the following upcoming conferences.
-
Solventum Hosts Inaugural Investor Day Ahead of Its Planned Spinoff from 3M
3/19/2024
Solventum will host its inaugural Investor Day in New York City ahead of its planned spinoff from 3M.
-
Biovica rReceives Positive Patent Notification for Immunotherapies
3/19/2024
Biovica International Biovica has received a positive International Preliminary Report on Patentability covering the use of TKa as a prognostic and monitoring marker in cancer treatment outside the CDK 4/6 inhibitor space, expanding the market potential for the DiviTum TKa technology by four to six times.
-
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
3/19/2024
Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radioconjugates as precision medicines, announced the Company has entered into a definitive agreement to be acquired by AstraZeneca.
-
PureTech Proposes $100 Million Capital Return
3/19/2024
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces a proposed capital return of $100 million to its shareholders by way of a tender offer.
-
Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC
3/19/2024
Portal Biotechnologies, Inc., a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.